Primalan® (Syrup) Instructions for Use
Marketing Authorization Holder
Pierre Fabre Medicament Production (France)
ATC Code
R06AD07 (Mequitazine)
Active Substance
Mequitazine (Rec.INN registered by WHO)
Dosage Forms
| Primalan® | Syrup 1.25 mg/2.5 ml: bottle 60 ml 1 pc. in a set with a measuring spoon | |
| Tablets 5 mg: 14 pcs. | ||
| Tablets 10 mg: 14 pcs. |
Dosage Form, Packaging, and Composition
Syrup from colorless to light yellow, with a fruity odor.
| 1 measuring spoon (2.5 ml) | 1 bottle | |
| Mequitazine | 1.25 mg | 30 mg |
Excipients: ascorbic acid, sucrose solution, tangerine essence flavor, methylparaben, propylparaben, water.
60 ml – dark glass type III bottles (1) in a set with a measuring spoon – cardboard packs.
Tablets white-cream (almost white) in color, oval, with a score on one side.
| 1 tab. | |
| Mequitazine | 10 mg |
Excipients: lactose, starch, acacia gum, colloidal silicon, talc, sodium carboxymethylcellulose, magnesium stearate.
14 pcs. – blisters (1) – cardboard packs.
Tablets white-cream (almost white) in color, round, with a score on one side.
| 1 tab. | |
| Mequitazine | 5 mg |
Excipients: lactose, starch, acacia gum, colloidal silicon, talc, sodium carboxymethylcellulose, magnesium stearate.
14 pcs. – blisters (1) – cardboard packs.
Clinical-Pharmacological Group
Histamine H1-receptor blocker. Antiallergic drug
Pharmacotherapeutic Group
H1 histamine receptor blocker
Pharmacological Action
Histamine H1-receptor blocker, a phenothiazine derivative. It has antiallergic, antipruritic, and anti-edema effects. The anticholinergic effect is weak. Prevents the release from mast cells of biologically active substances that are mediators of allergy and inflammation. Does not have a pronounced effect on the CNS. The action begins within 30 minutes and lasts for 24 hours.
Pharmacokinetics
Absorption is rapid and complete. Food intake does not affect the extent of absorption, but the rate of absorption is somewhat reduced. Time to reach Cmax in plasma after a single dose of 5 mg is 3.2 hours, 10 mg is 4 hours; Cmax in plasma is 3.26 ng/ml and 6.5 ng/ml, respectively.
It is well distributed in organs and tissues. Does not penetrate the blood-brain barrier. Metabolized in the liver to form active metabolites. T1/2 of the drug is 18 hours. Excreted as metabolites, mainly in feces, and only a small amount is excreted unchanged by the kidneys.
Indications
Symptomatic treatment of adults and children over 6 years of age:
- Perennial and seasonal allergic rhinitis;
- Acute and chronic recurrent urticaria;
- Allergic conjunctivitis;
- Atopic dermatitis.
ICD codes
| ICD-10 code | Indication |
| H10.1 | Acute atopic (allergic) conjunctivitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L28.0 | Lichen simplex chronicus (circumscribed neurodermatitis) |
| L50 | Urticaria |
| ICD-11 code | Indication |
| 9A06.70 | Atopic eczema of the eyelids |
| 9A60.01 | Acute atopic conjunctivitis |
| 9A60.02 | Allergic conjunctivitis |
| 9A60.0Y | Other specified papillary conjunctivitis |
| 9A60.0Z | Papillary conjunctivitis, unspecified |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA83.00 | Lichen simplex of vulva |
| EA83.01 | Lichen simplex of male genital organs |
| EA83.02 | Lichen simplex of perianal area |
| EA83.0Z | Lichen simplex of unspecified location |
| EA85.20 | Atopic hand eczema |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Orally, regardless of meals, with water. Adults and children over 12 years – 5 mg 2 times/day, in the morning and evening (before bedtime) or 10 mg once/day (in the evening).
Children from 6 to 12 years: with body weight less than 30 kg (6-10 years) – 2.5 mg 2 times/day (in the morning and evening) or 5 mg once/day (in the evening); with body weight from 30 to 40 kg (10-12 years) – 2.5 mg in the morning and 5 mg in the evening or 7.5 mg (1.5 tab.) once/day (in the evening). When taking the syrup, it should be taken into account that one measuring spoon of syrup (2.5 ml) contains 1.25 mg of the drug. The course of treatment depends on the nature of the disease.
Adverse Reactions
From the digestive system: dry mouth; in rare cases – dyspeptic disorders.
From the CNS: drowsiness (not pronounced and quickly passing), headache, feeling of fatigue, in some cases – mood lability in elderly patients and children.
Adverse reactions occur rarely, are usually mild and transient.
Contraindications
- Angle-closure glaucoma;
- Prostatic hypertrophy;
- Concomitant use of MAO inhibitors;
- Pregnancy;
- Lactation period;
- Children under 6 years of age;
- Hypersensitivity (including to other phenothiazine derivatives);
With caution – hepatic insufficiency (risk of accumulation), elderly age, tendency to constipation, epilepsy.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and lactation.
Use in Hepatic Impairment
With caution – hepatic insufficiency (risk of accumulation).
Pediatric Use
Contraindicated in children under 6 years of age.
Children from 6 to 12 years: with body weight less than 30 kg (6-10 years) – 2.5 mg 2 times/day (in the morning and evening) or 5 mg once/day (in the evening); with body weight from 30 to 40 kg (10-12 years) – 2.5 mg in the morning and 5 mg in the evening or 7.5 mg (1.5 tab.) once/day (in the evening). When taking the syrup, it should be taken into account that one measuring spoon of syrup (2.5 ml) contains 1.25 mg of the drug. The course of treatment depends on the nature of the disease.
Geriatric Use
With caution – elderly age.
Special Precautions
During treatment, it is necessary to refrain from consuming ethanol and from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Overdose
Symptoms (with accidental single ingestion of large doses): intensification of adverse reactions.
Treatment: no specific antidote. Gastric lavage, symptomatic therapy.
Drug Interactions
When taken concomitantly with antihypertensive drugs – enhancement of the hypotensive effect.
Enhances the effect of drugs that depress the CNS (antidepressants with sedative effect, barbiturates, benzodiazepines, clonidine, hypnotics, analgesics, antitussives, and antipsychotic drugs (neuroleptics).
Does not alter the effect of ethanol.
When used concomitantly with atropine and other drugs with anticholinergic action, tricyclic antidepressants of the imipramine type, antiparkinsonian drugs, myotropic antispasmodics, disopyramide, antipsychotic drugs, phenothiazine derivatives, an increase in side effects is possible.
Storage Conditions
Store in a place inaccessible to children at a temperature not exceeding 25°C (77°F), in a light-protected place.
Shelf Life
Shelf life – tablets – 3 years, syrup – 2 years.
Dispensing Status
The drug is dispensed by prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer